<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335890</url>
  </required_header>
  <id_info>
    <org_study_id>DERMA-ER-DC 09</org_study_id>
    <nct_id>NCT04335890</nct_id>
  </id_info>
  <brief_title>IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma</brief_title>
  <official_title>Phase I Vaccination Trial in Metastatic Uveal Melanoma Using IKKb-matured Dendritic Cells Loaded With Autologous Tumor-RNA + RNA Coding for Defined Antigens and Driver Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasumi International Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasumi International Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal
      melanoma not cureable with local therapy and needing systemic therapy. IKKb-matured Dendritic
      Cells loaded with autologous tumor-RNA + RNA coding for defined antigens and driver mutations
      will be added to a standard therapy chosen by the tumor board (either checkpoint blockade or
      chemotherapy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous infusion of 7.5 to 30 mio DCIKKb at 9 vaccination time points (week 1, 3, 7, 13,
      19, 25, 31, 37 and 42) and in intervals of 2, 4, and 6 intervals of 6 weeks) is scheduled;
      the first 4 patients will receive reduced doses for the first 4 vaccinations, namely 7.5 mio
      (1st and 2nd vaccination) and 15 mio (3rd and 4th vaccination) DC followed by the full dose
      of 30 mio for subsequent vaccinations. Patients number 5 to 8 will receive initially reduced
      doses of 15 mio (1st and 2nd vaccination) DC for the first 2 vaccinations, and the full dose
      of 30 mio for subsequent vaccinations. Patients number 8 to 12 will receive the full dose of
      30 mio cells from vaccination 1 onwards provided that no major side effects occurred.
      Patients will be vaccinated in a staggered approach by selectively decelerating release of
      the vaccine.

      DCIKKb = autologous, monocyte-derived DC that are matured with the standard cocktail
      (TNF-alpha, IL-1 beta, IL-6 and PGE2) and IKKb-RNA loaded by electroporation with 1)
      autologous PCR-amplified total tumor mRNA, 2) RNA coding for defined tumor associated
      antigens (TAA) namely gp100, tyrosinase, PRAME, MAGE-A3, IDO) and 3) RNA coding for driver
      mutations (GNAQ/GNA11Q209 or R183, or the less frequently occurring SF3B1R625, CYSLTR2L129Q
      or PLCB4D630) by electroporation; RNAs for selected TAAs are in stock and will be transfected
      into the DCs only if expressed in the individual tumor of a patient (shown by RNA sequencing
      of the tumor); RNAs for selected driver mutations are in stock and will be loaded into the
      DCs only if the respective mutation is found (proven by exome and RNA sequencing) in the
      individual tumor.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of DCIKKb</measure>
    <time_frame>1 year</time_frame>
    <description>Assesment of side effects using the Common Toxicity Criteria (CTC v4.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of DCIKKb</measure>
    <time_frame>1 year</time_frame>
    <description>Assesment of Quality of life using Quality of life EORTC QLQ-C30, Version 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs) of DCIKKb</measure>
    <time_frame>1 year</time_frame>
    <description>Assesment of side effects using the Common Toxicity Criteria (CTC v4.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of DCIKKb</measure>
    <time_frame>1 year</time_frame>
    <description>Assesment of side effects using the Common Toxicity Criteria (CTC v4.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolongation of median overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Assesment of survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of overall survival (OS) after 1 and 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>Assesment of survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of antigen specific CD8+ T cells and / or CD4+ T cells against TAA and mutated drivers</measure>
    <time_frame>2 years</time_frame>
    <description>Assesment of immune responses</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Melanoma, Uveal Metastatic</condition>
  <arm_group>
    <arm_group_label>DC IKKb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination with IKKb matured RNA loaded Dendritic Cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with IKKb matured Dendritic Cells</intervention_name>
    <description>IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination</description>
    <arm_group_label>DC IKKb</arm_group_label>
    <other_name>Dendritic Cell vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed unresectable stage IV metastatic uveal melanoma as per AJCC
             staging system 2014, 7th edition (updated 2018) not curable with local therapy
             modalities

          -  WHO performance status of 0, 1 or 2

          -  age from 18 and ≤ 75 years

          -  negative pregnancy test

          -  signed informed consent

        Exclusion Criteria:

          -  Major serious illness

          -  evidence for HIV-1, HIV-2, HTLV-1, HBV or HCV infection

          -  active autoimmune disease requiring immunosuppressive therapy

          -  splenectomy or radiation therapy of the spleen

          -  organ allografts

          -  pregnancy

          -  lactation

          -  psychiatric disorders

          -  severe organic brain syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Schuler-Thurner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatrice Schuler-Thurner, MD</last_name>
    <phone>0049 9131 85</phone>
    <phone_ext>45833</phone_ext>
    <email>beatrice.schuler-thurner@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Erdmann, MD</last_name>
    <phone>0049 9131 85</phone>
    <phone_ext>45833</phone_ext>
    <email>michael.erdmann@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Erlangen Dept. of Dermatology</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>B Schuler-Thurner, Associate Professor</last_name>
      <phone>+49 9131 853</phone>
      <phone_ext>5833</phone_ext>
      <email>experimentelle-immuntherapie@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Erdmann, MD</last_name>
      <phone>+49 9131 853</phone>
      <phone_ext>5833</phone_ext>
      <email>experimentelle-immuntherapie@uk-erlangen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Pfeiffer IA, Hoyer S, Gerer KF, Voll RE, Knippertz I, Gückel E, Schuler G, Schaft N, Dörrie J. Triggering of NF-κB in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy. Eur J Immunol. 2014 Nov;44(11):3413-28. doi: 10.1002/eji.201344417. Epub 2014 Sep 16.</citation>
    <PMID>25100611</PMID>
  </results_reference>
  <results_reference>
    <citation>Gerer KF, Erdmann M, Hadrup SR, Lyngaa R, Martin LM, Voll RE, Schuler-Thurner B, Schuler G, Schaft N, Hoyer S, Dörrie J. Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. Ther Adv Med Oncol. 2017 Jul;9(7):451-464. doi: 10.1177/1758834017712630. Epub 2017 Jun 13.</citation>
    <PMID>28717398</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S, Heindl LM, Holbach L, Keserü M, Knorr H, Koch K, Kruse F, Meiller R, Metz C, Meyer-ter-Vehn T, Much M, Reinsberg M, Schliep S, Seitz B, Schuler G, Süsskind D, Viestenz A, Wagenfeld L, Zeschnigk M. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma]. Ophthalmologe. 2015 Dec;112(12):1017-21. doi: 10.1007/s00347-015-0162-z. German.</citation>
    <PMID>26602097</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>Beatrice Schuler-Thurner, Ph.D</investigator_full_name>
    <investigator_title>PD Dr. Beatrice Schuler-Thurner</investigator_title>
  </responsible_party>
  <keyword>local treatment not sufficient</keyword>
  <keyword>systemic treatment indicated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

